v3.26.1
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Operating expenses:    
Research and development $ 1,545 $ 12,180
General and administrative 5,208 5,449
Restructuring and impairment charges 612 0
Total operating expenses 7,365 17,629
Loss from operations (7,365) (17,629)
Interest income 609 1,420
Gain on sale of nonfinancial asset 1,000 0
Interest expense 0 (347)
Net loss $ (5,756) $ (16,556)
Net loss per common share, basic (in dollars per share) $ (0.78) $ (2.27)
Net loss per common share, diluted (in dollars per share) $ (0.78) $ (2.27)
Weighted-average shares used to compute net loss per common share, basic (in shares) 7,343,909 7,305,658
Weighted-average shares used to compute net loss per common share, diluted (in shares) 7,343,909 7,305,658